| Literature DB >> 29025749 |
Marie-A Chaix1, Annie Dore1, Lise-Andrée Mercier1, François-Pierre Mongeon1, François Marcotte1, Réda Ibrahim1, Anita W Asgar1, Azadeh Shohoudi2, Fabien Labombarda1, Blandine Mondésert1, Nancy Poirier1, Paul Khairy3,2.
Abstract
BACKGROUND: There is a paucity of data regarding late-onset pulmonary hypertension (PH) in patients with transposition of the great arteries and atrial switch surgery. METHODS ANDEntities:
Keywords: Mustard baffle; Senning baffle; atrial switch surgery; pulmonary hypertension; transposition of great vessels
Mesh:
Year: 2017 PMID: 29025749 PMCID: PMC5721856 DOI: 10.1161/JAHA.117.006481
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics
| N=140 | |
|---|---|
| Age at first referral, y | 25.1±6.7 |
| Sex (female), N (%) | 52 (37.1) |
| Mustard baffle, N (%) | 118 (84.3) |
| Age at atrial switch surgery, | 20.9 (11.1, 32.3) |
| Diabetes mellitus, N (%) | 2 (1.4) |
| Dyslipidemia, N (%) | 1 (0.7) |
| Hypertension, N (%) | 12 (8.6) |
| Obesity, N (%) | 5 (3.6) |
| Active or past tobacco use, N (%) | 26 (18.6) |
| New York Heart Association class III or IV symptoms, N (%) | 6 (4.3) |
| Diagnosis of heart failure, N (%) | 8 (5.7) |
| Sustained atrial arrhythmia, N (%) | 37 (26.4) |
| Nonsustained or sustained ventricular tachycardia, N (%) | 7 (5.0) |
| Permanent pacemaker, N (%) | 43 (30.7) |
| Stenosis or thrombosis of the systemic baffle, N (%) | 26 (18.6) |
| Associated lesions at birth, N (%) | |
| One or more associated lesions | 50 (35.7) |
| Patent ductus arteriosus | 21 (15.0) |
| Pulmonary or subpulmonary stenosis | 16 (11.4) |
| Atrial septal defect | 6 (4.3) |
| Ventricular septal defect | 17 (12.1) |
| Residual lesions after surgery, N (%) | |
| One or more residual lesions | 16 (11.4) |
| Atrial septal defect | 6 (4.3) |
| Subpulmonary stenosis | 6 (4.3) |
| Ventricular septal defect | 5 (3.6) |
| Pulmonary artery stenosis | 1 (0.7) |
| Electrocardiographic parameters | |
| Sinus rhythm, N (%) | 82 (58.6) |
| QRS duration, ms | 107.3±25.1 |
| Ventricular pacing, N (%) | 10 (7.1) |
| QRS duration excluding ventricular pacing, ms | 104.1±18.5 |
| Echocardiographic parameters, N (%) | |
| Moderate or severe right ventricular dilatation | 80 (57.1) |
| Moderate or severe right ventricular systolic dysfunction | 38 (27.1) |
| Moderate or severe tricuspid regurgitation | 41 (29.3) |
| Pharmacologic therapy, N (%) | |
| Loop diuretic | 7 (5.0) |
| β‐Blocker | 27 (19.3) |
| ACE inhibitor or angiotensin receptor blocker | 63 (45.0) |
ACE indicates angiotensin‐converting enzyme.
Nonnormally distributed continuous variables are presented as median (interquartile range).
Characteristics at the Time of Cardiac Catheterization According to Whether or Not Patients Had PH
| PH (N=18) | No PH (N=15) |
| |
|---|---|---|---|
| Age at catheterization, y | 33.9±8.1 | 32.2±9.9 | 0.656 |
| Female sex, N (%) | 5 (27.8) | 6 (40.0) | 0.458 |
| Associated congenital heart lesions, N (%) | 7 (38.9) | 6 (40.0) | 0.948 |
| Mustard surgery, N (%) | 16 (88.9) | 12 (80.0) | 0.639 |
| Age at atrial switch surgery, | 26.0 (15.3, 43.2) | 17.9 (5.3, 19.2) | 0.211 |
| Time from surgery to catheterization, | 29.7 (26.0, 38.7) | 29.2 (22.6, 35.3) | 0.656 |
| Residual lesion after atrial switch surgery, N (%) | 4 (22.2) | 2 (13.3) | 0.665 |
| Stenosis or thrombosis of systemic baffle, N (%) | 4 (22.2) | 5 (33.3) | 0.697 |
| Echocardiogram at time of catheterization | |||
| Moderate or severe right ventricular dilatation, N (%) | 8 (44.4) | 7 (46.7) | 0.898 |
| Moderate or severe right ventricular dysfunction, N (%) | 14 (77.8) | 10 (66.7) | 0.697 |
| Moderate or severe tricuspid regurgitation, N (%) | 12 (66.7) | 7 (46.7) | 0.247 |
| At least mild mitral regurgitation, N (%) | 4 (22.2) | 5 (33.3) | 0.697 |
| At least mild pulmonary regurgitation, N (%) | 8 (50.0) | 4 (36.4) | 0.696 |
| Severe subpulmonary ventricular dysfunction, N (%) | 4 (22.2) | 0 (0.0) | 0.108 |
| Catheterization data | |||
| Systolic arterial pressure, mm Hg | 124±17 | 109±21 | 0.036 |
| Diastolic arterial pressure, mm Hg | 75±9 | 64±13 | 0.007 |
| Systolic PAP, mm Hg | 55±20 | 26±8 | <0.001 |
| Diastolic PAP, mm Hg | 23±9 | 8±4 | <0.001 |
| Mean PAP, mm Hg | 36±12 | 16±4 | <0.001 |
| PCWP, mm Hg | 28±8 | 15±6 | <0.001 |
| PVR, Wood units | 2.5±2.5 | 0.7±0.6 | <0.001 |
| Cardiac index, L/min per m2 | 2.4±0.7 | 2.5±0.6 | 0.714 |
| Systemic ventricular end‐diastolic pressure, mm Hg | 18±7 | 14±5 | 0.077 |
| Subpulmonary ventricular end‐diastolic pressure, mm Hg | 13±6 | 8±5 | 0.077 |
PAP indicates pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.
Nonnormally distributed continuous variables are presented as median (interquartile range).
Characteristics and Clinical Status of Individuals With PH
| Indication for Catheterization | Pt # | Age at Surgery, Months | Type of Postcapillary PH | PAP S/D (Mean), mm Hg | PCWP, mm Hg | PVR, Wood Units | TPG, mm Hg | DPG, mm Hg | Specific Management | Clinical Status at Last Follow‐Up |
|---|---|---|---|---|---|---|---|---|---|---|
| Heart failure or decreased exercise tolerance | 1 | 49 | Isolated | 62/29 (40) | 30 | 1.7 | 10 | −1 | Referral for cardiac transplantation | Improvement; removal from transplant list |
| 2 | 58 | Isolated | 55/34 (43) | 29 | 2.1 | 14 | 5 | |||
| 3 | 5 | Isolated | 58/20 (30) | 17 | 2.5 | 13 | 3 | No follow‐up available | ||
| 4 | 32 | Isolated | 47/17 (31) | 23 | 1.9 | 8 | −6 | Heart transplant | ||
| 5 | 43 | Isolated | 50/21 (33) | 26 | 1.8 | 7 | −5 | Listed for transplant; recurrent hospitalizations for heart failure | ||
| 6 | 25 | Combined | 86/40 (60) | 39 | 4.0 | 21 | 1 | Death | ||
| 7 | 21 | Isolated | 56/19 (36) | 29 | 1.7 | 7 | −10 | Pulmonary arterial hypertension therapy | Recurrent hospitalizations for heart failure | |
| 8 | 43 | Not determined | 45/18 (32) | 18 | ··· | 14 | 0 | Improvement | ||
| 9 | 44 | Isolated | 34/16 (26) | 22 | 0.8 | 4 | −6 | |||
| 10 | 28 | Isolated | 50/20 (30) | 25 | 0.8 | 5 | −5 | Death | ||
| 11 | 31 | Isolated | 45/21 (31) | 24 | 1.3 | 7 | −3 | Angioplasty of pulmonary baffle obstruction | Improvement | |
| 12 | 15 | Isolated | 45/20 (29) | 20 | 2.1 | 9 | 0 | TVR | Improvement | |
| 13 | 9 | Combined | 117/45 (73) | 32 | 10.2 | 41 | 13 | |||
| Severe tricuspid regurgitation | 14 | 17 | Isolated | 40/20 (28) | 23 | 1.26 | 5 | −3 | No change | |
| 15 | 152 | Isolated | 40/12 (30) | 22 | 1.7 | 8 | −10 | TVR | Death | |
| 16 | 18 | Isolated | 38/23 (31) | 20 | 2.9 | 11 | 3 | Improvement | ||
| Suspicion of superior systemic baffle stenosis | 17 | 41 | Isolated | 48/26 (32) | 25 | 1.5 | 7 | 1 | No change | |
| 18 | 4 | Isolated | 64/15 (35) | 28 | 1.5 | 7 | −13 |
DPG indicates diastolic pressure gradient; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; S/D, systolic/diastolic; TPG, transpulmonary gradient; TVR, tricuspid valve replacement.
Baseline Characteristics Associated With PH in Univariable and Multivariable Logistic Regression Analyses
| N=140 | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| Odds Ratio (95% CI) |
| Odds Ratio (95% CI) |
| |
| Systemic hypertension | 6.3 (1.8, 22.8) | 0.005 | 9.4 (2.2, 39.4) | 0.002 |
| Ventricular arrhythmias | 5.9 (1.2, 28.9) | 0.029 | ||
| History of heart failure or NYHA class III or IV | 38.2 (7.1, 206.6) | <0.001 | 49.8 (8.6, 289.0) | <0.001 |
| QRS duration, per ms | 1.024 (1.006, 1.041) | 0.008 | ||
| Moderate to severe tricuspid regurgitation | 2.8 (1.0, 7.7) | 0.044 | ||
CI indicates confidence interval; NYHA, New York Heart Association.
Characteristics at Last Follow‐Up
| PH (N=18) | No Known PH (N=122) |
| |
|---|---|---|---|
| Diabetes mellitus, N (%) | 3 (16.7) | 2 (1.6) | 0.015 |
| Dyslipidemia, N (%) | 2 (11.1) | 1 (0.8) | 0.044 |
| Hypertension, N (%) | 6 (33.3) | 16 (13.1) | 0.039 |
| Obesity, N (%) | 4 (22.2) | 5 (4.1) | 0.016 |
| Active or past tobacco use, N (%) | 4 (22.2) | 28 (23.0) | 1.000 |
| New York Heart Association class III or IV symptoms, N (%) | 5 (27.8) | 5 (4.1) | 0.003 |
| Hospitalization for heart failure, N (%) | 9 (50.0) | 2 (1.6) | <0.001 |
| Sustained atrial arrhythmia, N (%) | 16 (88.9) | 58 (47.5) | 0.001 |
| Nonsustained or sustained ventricular tachycardia, N (%) | 8 (44.4) | 19 (15.6) | 0.008 |
| Permanent pacemaker, N (%) | 11 (61.1) | 49 (40.2) | 0.094 |
| Implantable cardioverter‐defibrillator, N (%) | 5 (27.8) | 4 (3.3) | 0.002 |
| Tricuspid valve surgery (replacement or annuloplasty), N (%) | 5 (27.8) | 2 (1.6) | <0.001 |
| Stenosis or thrombosis of the systemic baffle, N (%) | 7 (38.9) | 36 (29.5) | 0.421 |
| Echocardiographic parameters, N (%) | |||
| Moderate or severe right ventricular dilatation | 12 (70.6) | 89 (73.6) | 0.776 |
| Moderate or severe right ventricular systolic dysfunction | 11 (61.1) | 41 (33.6) | 0.024 |
| Moderate or severe tricuspid regurgitation | 6 (33.3) | 39 (32.0) | 0.908 |
| Pharmacologic therapy, N (%) | |||
| Loop diuretic | 9 (50.0) | 6 (4.9) | <0.001 |
| β‐Blocker | 15 (83.3) | 44 (36.1) | <0.001 |
| ACE inhibitor or angiotensin receptor blocker | 11 (61.1) | 41 (33.6) | 0.024 |
| Mortality | |||
| Death of any cause, N (%) | 3 (16.7) | 4 (3.3) | 0.045 |
| Cardiovascular death, N (%) | 3 (16.7) | 3 (2.5) | 0.028 |
| Age at death, y | 33.0±7.2 | 30.7±6.6 | 1.000 |
ACE indicates angiotensin‐converting enzyme; PH, pulmonary hypertension.
Includes patients with moderate or severe tricuspid regurgitation following tricuspid valve surgery.
Figure 1Kaplan‐Meier curves depicting all‐cause mortality according to the presence or absence of pulmonary hypertension.